Catalent UK Swindon Zydis Limited (trading as Catalent Pharma Solutions) was ordered to pay over £100,000 in fi nes and costs in December 2010 for exposing ten of its employees to Olanzapine, a hazardous substance. Charges were brought under the Health and Safety at Work etc Act 1974 and four different regulations in the Control of Substances Hazardous to Health Regulations 2002 (COSHH).
Olanzapine, an ingredient of a commonly prescribed anti-psychotic drug, had been confi rmed as the potential cause of previous cases of allergic contact dermatitis at Catalent’s factory in Swindon. Despite two confi rmed cases in October and December 2007 and a visit by HSE, the company failed to review its risk assessment until February 2008. During HSE’s investigation into the incidents, a further eight employees were confi rmed as suffering from allergic contact dermatitis caused by contact with the substance.
Regulation 6 of COSHH requires that employers review risk assessments regularly and forthwith if there is reason to suspect that the existing risk assessment is no longer valid or if the results of statutory monitoring show it to be necessary. Amongst other things, Catalent failed to react quickly, as it is required to do, to reduce the risk of further injury.